Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(0.43)
# 3,885
Out of 4,810 analysts
125
Total ratings
12.73%
Success rate
-38.6%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMUX Immunic | Reiterates: Buy | $10 | $0.99 | +912.15% | 3 | Apr 15, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterates: Buy | $10 | $2.20 | +354.55% | 12 | Apr 4, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $30 → $42 | $13.88 | +202.59% | 7 | Apr 2, 2025 | |
| SRZN Surrozen | Reiterates: Buy | $32 | $9.75 | +228.21% | 2 | Apr 2, 2025 | |
| FBLG FibroBiologics | Reiterates: Buy | $12 | $0.96 | +1,153.79% | 4 | Apr 1, 2025 | |
| IRD Opus Genetics | Reiterates: Buy | $8 | $0.80 | +897.51% | 3 | Apr 1, 2025 | |
| HLVX HilleVax | Reiterates: Neutral | $2 | $1.65 | +21.21% | 6 | Mar 31, 2025 | |
| KOD Kodiak Sciences | Reiterates: Neutral | $3 | $2.31 | +29.87% | 4 | Mar 31, 2025 | |
| OPT Opthea | Downgrades: Neutral | $12 → $2 | $3.41 | -41.35% | 7 | Mar 25, 2025 | |
| UBX Unity Biotechnology | Maintains: Buy | $8 → $4 | $0.97 | +312.37% | 7 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $1.12 | +78.57% | 16 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $9 | $9.19 | -2.07% | 7 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $3.51 | +184.90% | 4 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $0.09 | +2,069.20% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $8.72 | +244.04% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $4.77 | +487.00% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $3.10 | +1,061.29% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $3.23 | +828.79% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $23.89 | +59.06% | 3 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $188.51 | -85.15% | 1 | Aug 22, 2023 |
Immunic
Apr 15, 2025
Reiterates: Buy
Price Target: $10
Current: $0.99
Upside: +912.15%
Aldeyra Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $10
Current: $2.20
Upside: +354.55%
Mineralys Therapeutics
Apr 2, 2025
Maintains: Buy
Price Target: $30 → $42
Current: $13.88
Upside: +202.59%
Surrozen
Apr 2, 2025
Reiterates: Buy
Price Target: $32
Current: $9.75
Upside: +228.21%
FibroBiologics
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $0.96
Upside: +1,153.79%
Opus Genetics
Apr 1, 2025
Reiterates: Buy
Price Target: $8
Current: $0.80
Upside: +897.51%
HilleVax
Mar 31, 2025
Reiterates: Neutral
Price Target: $2
Current: $1.65
Upside: +21.21%
Kodiak Sciences
Mar 31, 2025
Reiterates: Neutral
Price Target: $3
Current: $2.31
Upside: +29.87%
Opthea
Mar 25, 2025
Downgrades: Neutral
Price Target: $12 → $2
Current: $3.41
Upside: -41.35%
Unity Biotechnology
Mar 25, 2025
Maintains: Buy
Price Target: $8 → $4
Current: $0.97
Upside: +312.37%
Mar 21, 2025
Reiterates: Neutral
Price Target: $2
Current: $1.12
Upside: +78.57%
Mar 21, 2025
Downgrades: Neutral
Price Target: $18 → $9
Current: $9.19
Upside: -2.07%
Mar 19, 2025
Maintains: Buy
Price Target: $7 → $10
Current: $3.51
Upside: +184.90%
Mar 14, 2025
Reiterates: Neutral
Price Target: $2
Current: $0.09
Upside: +2,069.20%
Mar 12, 2025
Reiterates: Buy
Price Target: $30
Current: $8.72
Upside: +244.04%
Mar 7, 2025
Reiterates: Buy
Price Target: $28
Current: $4.77
Upside: +487.00%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $3.10
Upside: +1,061.29%
Nov 19, 2024
Reiterates: Buy
Price Target: $30
Current: $3.23
Upside: +828.79%
Nov 7, 2024
Reiterates: Buy
Price Target: $38
Current: $23.89
Upside: +59.06%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $188.51
Upside: -85.15%